← Human Trials & Peer-Reviewed Studies
Efficacy and safety of individualized growth hormone treatment in adult Japanese patients with growth hormone deficiency.
Plain-language guide to PMID 18395480 (2008): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 18395480
- Journal
- Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Chihara K et al. (5 authors)
- DOI
- 10.1016/j.ghir.2008.02.002
- Registered trial
- NCT00184743, NCT00519558
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, both men and women.
Adult Japanese GH-deficient patients (peak GH<3 ng/mL).
How the Study Was Run
In design terms this was a randomized, double-blind, open-label and placebo-controlled study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
Trunk and total body fat (BF), lean body mass (LBM), and adverse events were determined.
What Was Measured
PubMed files the paper under topics including Body Composition, Deficiency Diseases, Growth Disorders, Hormone Replacement Therapy, Human Growth Hormone, Insulin-Like Growth Factor I and Japan.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2008 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.